The Onco-D-Clare test by RGCC is an advanced cancer screening tool that combines molecular biology with machine learning algorithms to detect cancer with remarkable precision, even before symptoms appear. Here’s how the test works:

Blood Sample Collection

A small blood sample is drawn from the individual and prepared for analysis. This non-invasive procedure ensures minimal discomfort while providing critical information.

Isolation of Peripheral Blood Mononuclear Cells (PBMCs)

From the blood sample, peripheral blood mononuclear cells (PBMCs) are isolated. These cells, which include lymphocytes and monocytes, are critical for immune system function and serve as the foundation for the test.

Gene Expression Analysis

Gene expression analysis is performed on over 90 specific genes within the PBMCs. This step measures how active these genes are, creating a unique gene expression profile for the sample.

Machine Learning Classification

The gene expression profile is analyzed using sophisticated machine learning algorithms trained to distinguish between healthy and cancerous patterns.

• The algorithm compares the sample's profile against validated data to determine if the expression patterns align with those found in cancerous cells.
• This approach enables the test to classify the sample as either cancerous or healthy with exceptional accuracy.

Results and Insights

The Onco-D-Clare test delivers results with approximately 93% accuracy, offering individuals a clear picture of their cancer risk or status.

• If the test identifies a cancerous classification, further diagnostic steps (e.g., OncoTrace or Onconomics Plus) can refine the diagnosis and inform treatment strategies.
• If classified as healthy, the test provides reassurance and valuable insights for preventive health planning.

Key Benefits of the Onco-D-Clare Test

1. Early Detection: Identifies cancer activity at a molecular level, often before symptoms develop or traditional diagnostics detect abnormalities.
2. Non-Invasive: Requires only a simple blood draw, avoiding invasive procedures like biopsies.
3. High Accuracy: Clinically validated with an accuracy rate of approximately 93%.
4. Informed Decision-Making: Provides essential data to help individuals make proactive, well-informed decisions about their health and future.

The Onco-D-Clare test empowers individuals with actionable information, enabling early intervention and personalized care when it matters most. This groundbreaking tool is redefining how cancer is detected, giving patients and healthcare providers the ability to act before the disease progresses.